Stock Analiz

BSX vs MDLN stock comparison

Boston Scientific vs. Medline · data as of November 13, 2026

Boston Scientific (BSX) has a market value of about $64.3B, Medline (MDLN) about $51.9B. Over their latest twelve months Boston Scientific had revenue of $21.1B and Medline $30.7B.

On our five checks Boston Scientific scores higher: 3.0 out of 5 (average) against 1.0 (weak).

By area, the stronger company is Boston Scientific on value; Boston Scientific on future growth; Boston Scientific on track record; Boston Scientific on financial health.

Boston Scientific is cheaper on earnings (P/E 18.8 vs. 89.7).

Boston Scientific leads on 14 of the compared lines and Medline on 6.

Side by side

BSXMDLN
Size and price
Market cap$64.3B$51.9B
Share price$44.34$39.47
Score
Overall score (of 5)3.01.0
Value30
Future growth52
Track record20
Financial health42
Shareholder returns11
Valuation
P/E (TTM)18.889.7
Forward P/E14.426.2
Price / free cash flow19.327.4
Price / sales3.11.7
EV / EBITDA14.122.6
PEG——
DCF value vs. price−58%−48%
Business
Revenue$21.1B$30.7B
Net income$3.5B$566M
Free cash flow$3.3B$1.9B
Net margin16.6%1.8%
Gross margin (5-yr avg.)68.9%26.4%
ROIC (5-yr avg.)5.9%8.6%
Growth
Revenue growth (1 yr)19.9%11.5%
Revenue growth (5 yrs, per year)15.2%—
EPS growth (5 yrs, per year)——
Balance sheet and payouts
Net cash (cash minus debt)-$11.3B-$9.1B
Dividend yieldNoneNone
Shareholder yield0.0%0.1%
Analysts
Upside to average target+12%+15%
Consensus ratingBuyBuy

Highlighted = the better figure on that line. Revenue, net income and free cash flow: BSX TTM to September 30, 2026, MDLN TTM to September 30, 2026. Not investment advice.

Frequently asked questions

Which is the better stock, Boston Scientific or Medline?

We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Boston Scientific scores 3.0 out of 5 and Medline 1.0; the table shows where each one is stronger.

Is Boston Scientific cheaper than Medline?

On trailing earnings, Boston Scientific trades at a P/E of 18.8 and Medline at 89.7, so Boston Scientific is cheaper by this measure. A lower P/E can also reflect slower expected growth.

Full Boston Scientific analysis → Full Medline analysis →

More comparisons

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.